Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the ...

Challenges in patient selection for surgical options in V600E BRAF–mutated metastatic colorectal cancer.

[10] Targeted therapies for cancer tend to be most effective when the therapeutic compound inhibits a pathway that is constitutively activated during the early stages of tumor development ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Mutant samples (columns/black bars) are sorted by grouped oncogene mutations and by tumor type (color legend ... (B) Incidence of BRAF mutations and co-occurring mutations in any RAS gene.

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ ...

We played a major role in characterising the BRAF gene and its role in cancer, increasing our understanding of malignant melanoma. Our work on the gene and the structure of the BRAF protein ...

"These data from the BREAKWATER study show the potential for this targeted treatment regimen to become the new standard of care for people with BRAF V600E-mutant metastatic colorectal cancer ...

FoundationOne CDx is now FDA-approved as the first companion diagnostic for tovorafenib, enabling targeted treatment for ...

“These results of this first analysis were the basis for the first approval of a targeted therapy regimen for use in the first-line setting for patients with metastatic colorectal cancer with a BRAF ...